Allicin was previously reported to prevent the development of cardiac remodeling and progression of cardiac hypertrophy to cardiac dysfunction by enhancing Nrf2 antioxidant signaling pathways [35]. Here, NFE2L2 is linked to cardiac hypertrophy.